BACK TO CONTENTS   |    PDF   |    PREVIOUS   |    NEXT

Title

Epitope mapping of gp350/220 conserved domain of epstein barr virus to develop nasopharyngeal carcinoma (npc) vaccine

 

Authors

Loly Sabrina Sitompul1, 2, Nashi Widodo1*, M Sasmito Djati1 & Didik H Utomo1

 

Affiliation

1Biology Department, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia; 2Academy of Health Analyst, Jayapura University of Science and Technology, Papua, Indonesia

 

Email

widodo@ub.ac.id; *Corresponding author

 

Article Type

Hypothesis

 

Date

Received May 14, 2012; Accepted May 24, 2012; Published May 31, 2012

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor in the nasopharyngeal epithelial cells that caused by many factors, one of which is the viral infection of EBV (Epstein Barr Virus). The standard treatments to cure NPC still have not been encouraging. The prevention through vaccination is an effective way to stop the disease. However, EBV vaccine being able to cover all variants of virus is still not available yet. Therefore, we identified the conserve region of glycoprotein 350/220 of EBV which has immunogenic and antigenic properties. The glycoprotein 350/220 is viral surface protein responsible to bind CR2 receptor, mediated EBV to enter the host cell. The conserved domain is crucial for EBV in infecting host cells. Further, by blocking CR2 binding domain of gp350/220 using antibody will inhibit EBVís spreading, and provoke an immune system to eliminate the virus in a patient. Glycoprotein 350/220 from all variants of Epstein-Barr virus was retrieved from NCBI. The conserved domain of gp350/220 was identified by aligning the protein sequences and structures. The polymorphic structure was used as a template for docking analysis to identify the resemblance of amino acid from polymorphic variants of gp350/220 that binds CR2. The epitope mapping of gp350/220 was done by Discotope BepiPred method. The result revealed that the conserved region of gp350/220 was predicted to have an epitope, QNPVYLIPETVPYIKWDNC residue, and it does not have any similarities to the humanís cell surface protein. Therefore, it can be used as a reference to develop vaccine to prevent NPC.

 

Keywords

EBV, CR2, NPC, gp350/220, Conserved region, Bioinformatics, Epitope mapping, Vaccine

Citation

Sitompul et al. Bioinformation 8(10): 479-482 (2012)
 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.